NCT01683058View on ClinicalTrials.gov

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole IM Depot

Aripiprazole IM Depot 400 mg or 300 mg

Trial Locations (38)

10090

Zagreb

11423

Holliswood

19139

Philadelphia

20016

Washington D.C.

30308

Atlanta

32810

Orlando

33162

North Miami

33301

Fort Lauderdale

33308

Fort Lauderdale

33334

Fort Lauderdale

34741

Kissimmee

39232

Flowood

44317

Popovača

45417

Dayton

60169

Hoffman Estates

63118

St Louis

63128

St Louis

70629

Lake Charles

72201

Little Rock

72764

Springdale

75231

Dallas

75243

Dallas

77007

Houston

78731

Austin

78754

Austin

90660

Pico Rivera

90746

Carson

90813

Long Beach

91403

Sherman Oaks

91950

National City

92025

Escondido

92102

San Diego

92123

San Diego

92701

Santa Ana

92845

Garden Grove

94612

Oakland

08053

Marlton

LV-5417

Daugavpils

Sponsors
All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY